News

Six months of treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) significantly improved lung function and nutritional status in two adults with cystic fibrosis (CF) caused by the rare mutation M1101K, according to two cases described in Canada. “Our cases not only demonstrate the therapeutic benefit of [Trikafta] in individuals with non-F508del…

Trikafta, a combination of elexacaftor, tezacaftor, and ivacaftor, lowered the number of Pseudomonas aeruginosa bacteria in the nose and sinuses of people with cystic fibrosis (CF) taking part in a small study. Mucus from the sinuses — air-filled pockets in the skull — can enter the lungs, so…

The pediatric and adult cystic fibrosis programs at Geisinger Medical Center have received an award from the Cystic Fibrosis Foundation (CFF) for their work in improving the care of people with cystic fibrosis (CF). Given annually, the CFF’s Quality Improvement Award recognizes centers that work continuously to improve…

A high degree of genetic diversity was found among strains of Pseudomonas aeruginosa bacteria initially infecting the lungs of people with cystic fibrosis (CF), a study reports. Over a seven-year follow-up, the majority of CF patients experience a recurrence of the bacteria, with one-third of those being infected…

Moligo Technologies is teaming up with Nationwide Children’s Hospital on a new project to develop a non-viral gene therapy approach for treating cystic fibrosis (CF) and other diseases that affect the lungs. Instead of using a modified virus to deliver a gene therapy into a patient’s body, the…

Parents of adolescents and young adults with cystic fibrosis (CF) retain a sense of responsibility for their children as they transition into adult healthcare services, and they can be frustrated by the changes demanded, an interview study reported. Healthcare providers should recognize the evolving roles of both patients and…

Kaftrio and Symkevi — marketed in the U.S. as Trikafta and Symdeko, respectively — may be effective in treating people with cystic fibrosis (CF) caused by rare mutations, according to a new study from the U.K. Both treatments were found to improve lung function and to ease…

Bacteria called Streptococcus parasanguinis may help inhibit the harmful effects of a Pseudomonas aeruginosa infection in the lungs of cystic fibrosis (CF) patients by modulating inflammation and increasing production of a metabolite called nitrite, recent preclinical research suggests. Previous research has linked these beneficial, or commensal, bacteria to…

A new study called ENHANCE is seeking to better understand the current effect of cystic fibrosis (CF) in young children. “There is so much to learn about the changes that are happening in children with CF, we are really excited about this new study,” Paul McNally, MD, a professor…

Treatment with Kaftrio eased gastrointestinal symptoms in people with cystic fibrosis (CF), ages 12 and older, according to a real-world study in the U.K and Ireland. The treatment’s maximum effect was achieved after two months and included a decline in gut inflammation. The study, “Reduction in abdominal…